Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
about
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorderPreclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonistBehavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic DrugsGlutamate receptor ion channels: structure, regulation, and functionUnprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseaseControl of assembly and function of glutamate receptors by the amino-terminal domain.Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic prospects for Parkinson disease.A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.Radiolabelling of 1,4-disubstituted 3-[18F]fluoropiperidines and its application to new radiotracers for NR2B NMDA receptor visualization.Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency.Development of PET and SPECT probes for glutamate receptors.
P2860
Q24602988-E35AAD6A-2800-48EE-8BE8-3FF5B67D8280Q26750021-3FE765F9-7AAD-4F37-8A65-68142C074F58Q27300104-0E696539-88B0-431B-9019-9F0C93903DB7Q28290774-A95DCF74-21D8-4DC2-ADC9-64B0CACAA311Q28542729-04C46BAE-0E90-4FB8-AE79-5AA611D913C6Q34310112-8BB66E3A-8898-4518-9845-ECCD6E5663A9Q37509323-C3BF3E9F-822C-419D-B81D-1C9B92BD944DQ38056852-D85D7558-26C6-4540-AB7A-514D5783D907Q38137889-7BFF3BE0-E1F1-436A-9265-4983EFAB7A7EQ38174986-5BAE04CE-2130-4994-93F0-3B246B736B2DQ38190016-018DC7DF-93BD-4B9B-AB0D-155CE0325F87Q38285126-36BC3DC9-F71F-4B86-9388-35DDF0C1787AQ38602173-73496A98-D24F-4D85-A118-B3524B56EEF8Q38658203-2D00E1FD-1301-4385-8805-1D6481A8C08FQ47723604-9084798C-15D7-4B72-B701-8BAFE467FC51Q48364623-6E7F9814-717F-4A4A-89C3-4A8121628249Q51010186-7253E42E-FEE0-43EC-8F4F-2E1C700AE949Q53015251-10A7276E-1E34-434B-9E3C-1E417C56AC48
P2860
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Single-dose administration of ...... moderate Parkinson's disease.
@en
Single-dose administration of ...... moderate Parkinson's disease.
@nl
type
label
Single-dose administration of ...... moderate Parkinson's disease.
@en
Single-dose administration of ...... moderate Parkinson's disease.
@nl
prefLabel
Single-dose administration of ...... moderate Parkinson's disease.
@en
Single-dose administration of ...... moderate Parkinson's disease.
@nl
P2093
P2860
P356
P1476
Single-dose administration of ...... moderate Parkinson's disease.
@en
P2093
Aaron Ellenbogen
Carol Addy
Chris Assaid
Daniel Tarsy
David Hreniuk
H A Jinnah
James Tetrud
John Wagner
Keith Gottesdiener
Louis Kirby
P2860
P304
P356
10.1177/0091270009336735
P577
2009-06-02T00:00:00Z